Digital stethoscope maker Eko nets $65M to develop home telehealth offerings

Duo and app on a smartphone
The proceeds will be used to expand the use of Eko's devices in hospitals and clinics—and help power the launch of an AI monitoring platform for patients at home, with a focus on heart and lung conditions. (Eko)

As the use of telehealth continues to surge—promising a way to deliver distanced care in spite of the coronavirus, and potentially a new normal in a post-pandemic world—the makers of a digital, connected stethoscope have raised new funds to expand its remote disease screening programs.

Eko secured $65 million in a series C venture capital round, led by Highland Capital Partners and Questa Capital, alongside additional backers in Artis Ventures, DigiTx Partners, NTTVC, 3M Ventures and other investors.

The proceeds will be used to further develop the use of the company’s devices in hospitals and clinics—and fuel the launch of an artificial intelligence-powered monitoring platform for patients at home with a focus on heart and lung conditions.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

“The explosion in demand for virtual cardiac and pulmonary care has driven Eko’s rapid expansion at thousands of hospitals and healthcare facilities, and we are excited for how this funding will accelerate the growth of our cardiopulmonary platform,” Eko co-founder and CEO Connor Landgraf said.

The company’s Duo stethoscope captures both heart sounds and electrocardiogram readings, and is connected to an AI program that received an FDA clearance at the top of this year to detect the signs of atrial fibrillation and heart murmurs.

RELATED: AstraZeneca taps digital stethoscope maker Eko to support its heart failure research

“The massive market need for telehealth is not going away,” said Rob Toews, principal at Highland Capital Partners. “Regulatory and reimbursement changes have been underway to support this growth. Eko is uniquely positioned in this space because their technology addresses crucial clinical needs that other companies cannot satisfy, and Eko’s platform is very easy to deploy and scale.”

Eko’s ultimate goal is to make its AI analyses a standard inclusion to every routine physical exam performed in a doctor’s office—while at the same time helping people to avoid clinic visits altogether when possible.

In October, Eko teamed up with 3M to develop a digital version of its ubiquitous Littmann stethoscope brand, used by healthcare professionals worldwide. Built off of 3M’s cardiology-focused model, the digital version aims to amplify subtle heart sounds up to 40 times while also canceling out unwanted background noise.

Suggested Articles

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.

Baxter has received clearance from the FDA for the latest version of its automated peritoneal dialysis system designed for home use.

ATAI Life Sciences is topping off a busy year with a $125 million financing, which will push two programs through phase 2 readouts.